Kathryn Kelly, MD
Internal Medicine · Silver Spring, MDNPI 1649447228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.
Across 136 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$658
- Novo Nordisk$588
- Pfizer$248
- Lilly USA, LLC$211
- Gilead$160
- AstraZeneca$149
- plus $882 from 23 others
Across 14 payments — averaging $37,898 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$433K
- AstraZeneca$47K
- Pfizer$28K
- Sanofi US Services Inc.$23K
What the payments were for
- Food & beverage$2,896100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $658 |
| Novo Nordisk | 20 | $588 |
| Pfizer | 15 | $248 |
| Lilly USA, LLC | 11 | $211 |
| Gilead | 7 | $160 |
| AstraZeneca | 8 | $149 |
| Sanofi | 2 | $130 |
| Biohaven Pharmaceuticals, Inc. | 3 | $67 |
| Eisai Inc. | 4 | $62 |
| Inspire Medical Systems, Inc. | 2 | $60 |
| GSK | 3 | $58 |
| Exact Sciences | 3 | $55 |
| Lumenis, Inc | 1 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Boehringer Ingelheim | 2 | $40 |
| Amgen | 2 | $37 |
| Phadia US Inc. | 2 | $33 |
| GE HealthCare | 2 | $32 |
| Abbott | 2 | $26 |
| Novartis | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Nevro Corp. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $19 |
| TMS Neurohealth Centers Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$114
How this compares
$2,896 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $53,995 |
| MounjaroTirzepatide | 19 | $40,881 |
| JardianceEmpagliflozin | 32 | $38,687 |
| EliquisApixaban | 40 | $34,077 |
| JanuviaSitagliptin Phosphate | 17 | $20,417 |
| TrulicityDulaglutide | 15 | $16,571 |
| LinzessLinaclotide | 19 | $16,256 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $15,028 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $12,943 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $7,082 |
| Sucralfate | 16 | $5,364 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $4,390 |
| VascepaIcosapent Ethyl | 12 | $4,036 |
| Lidocaine | 22 | $3,972 |
| Gabapentin | 88 | $3,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $211 | $57,45134 claims |
| Novo NordiskOzempic | $588 | $53,99542 claims |
| Boehringer IngelheimJardiance | $40 | $38,68732 claims |
| PfizerEliquis, Paxlovid | $248 | $36,90358 claims |
| AbbVieLinzess | $658 | $16,25619 claims |
| GSKTrelegy Ellipta | $58 | $15,02817 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $40 | $4,39011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Silver Spring
- Jose BonelliSilver Spring$40K
- Luis GonzalezSilver Spring$20K
- T Lydel NewsomeSilver Spring$19K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.